Health Catalyst Inc

Health Catalyst Inc(HCAT)股票分析

$1.500

-0.085 (-5.66%)收盘时

Loading chart…
最高
1.590
开盘
1.590
成交量加权均价
1.51
成交量
336.35K
市值
357.16M
最低
1.450
成交额
509.00K
企业价值/息税折旧摊销前利润(TTM)
6.09

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

AI 分析 of Health Catalyst Inc (HCAT)

卖出

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

估值指标

Health Catalyst Inc(HCAT)当前预期市盈率为 10.00,5 年平均预期市盈率为 -7.88。

预期市盈率

合理
5 年均值 P/E
-7.88
当前P/E
10.00
高估
103.22
低估
-118.99

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-53.03
当前EV/EBITDA
6.09
高估
98.36
低估
-204.42

预期市销率

合理
5 年均值 P/S
1.83
当前P/S
0.58
高估
3.43
低估
0.24

Alphio AI 对 HCAT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%HCAT

$4.94

情景价格

基

基准

基准 · 50%HCAT

$4.25

情景价格

悲

悲观

悲观 · 25%HCAT

$4.22

情景价格

持有 HCAT 的大户

F

First Light Asset Management, LLC

+ 持有HCAT

+0.00%

3个月收益率

事件时间线

2026-09-08 (ET)

09:00:00

Health Catalyst Appoints Simeon Kohl as CEO

2026-08-06 (ET)

17:30:00

Health Catalyst Closes Sale of Vitalware for $147 Million

17:00:00

Sees FY26 Adjusted EBITDA of $18M to $18.5M

17:00:00

Company Reports Q2 Revenue of $70.49M, Exceeding Expectations

17:00:00

Sees Q3 Adjusted EBITDA of $0-$500K

资讯

HCAT 常见问题 —— 由 Alphio AI 解答

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. It operates in the Technology sector (SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ET industry).

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易